KRAS and ovarian serous adenocarcinoma: It behaves in a more indolent fashion than HGSOC, and has low response rates to chemotherapy and hormonal agents.6 They are commonly diagnosed at an advanced stage and OS is poor.9, 15 Women with low grade serous ovarian cancer rarely have a family history of breast and/or ovarian cancer.16 In contrast to HGSOC, pathogenic somatic variants have been found in KRAS, NRAS, BRAF, ERBB2 and PI3KCA oncogenes.6 The mitogen‐activated protein kinase (MAPK) pathway is frequently activated, accomplished by variants in KRAS and BRAF. 16